Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple
Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple have?
Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple has 10 citations in the OpenAlex counts ScholarIQ stores.
When was Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple published?
Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple has 2020 year in the ScholarIQ index.
What is the open-access status of Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple?
Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple has closed oa status in the ScholarIQ index.
What is the DOI of Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple?
The DOI for Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple is on the source record.
What is the PMID of Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple?
The PMID for Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple is on the source record.
What is the OpenAlex record for Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple?
The OpenAlex for Real world outcomes with <scp>Bortezomib Thalidomide dexamethasone</scp> and <scp>Cyclophosphamide Bortezomib dexamethasone</scp> induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple is on the source record.